Boxer Capital, LLC
Boxer Capital, LLC's purchase track record
How the stock did after each of Boxer Capital, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/13/2023 | TNGX | $8.72M | +42.3% | -4.3% | +18.4% |
| 8/11/2023 | TNGX | $2.45M | +11.3% | +65.3% | +12.6% |
| 10/12/2022 | TNGX | $547K | +78.2% | +3.4% | +14.4% |
| 10/4/2022 | TNGX | $1.21M | +91.4% | +12.0% | +8.2% |
| 12/17/2021 | TYRA | $1.64M | +1.7% | -58.0% | -20.5% |
| 9/17/2021 | TYRA | $10.00M | -37.2% | -36.1% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Transaction History
| TYRA | ▲ Buy | Grant | 63,412 | $825K | 2/6/2024 | View on chart |
| TNGX | ▲ Buy | Open Market | 500,000 | $3.4M | 10/16/2023 | View on chart |
| TNGX | ▲ Buy | Open Market | 750,000 | $5.3M | 10/13/2023 | View on chart |
| TNGX | ▼ Sell | Open Market | 50,000 | $496K | 10/9/2023 | View on chart |
| TNGX | ▼ Sell | Open Market | 175,000 | $1.7M | 10/9/2023 | View on chart |
| TNGX | ▲ Buy | Open Market | 475,000 | $2.4M | 8/11/2023 | View on chart |
| TNGX | ▲ Buy | Open Market | 70,000 | $325K | 10/13/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 50,000 | $222K | 10/12/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 117,000 | $498K | 10/11/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 70,394 | $286K | 10/6/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 45,500 | $179K | 10/5/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 40,500 | $155K | 10/5/2022 | View on chart |
| TNGX | ▲ Buy | Open Market | 25,606 | $94K | 10/4/2022 | View on chart |
| TYRA | ▲ Buy | Open Market | 125,000 | $1.6M | 12/17/2021 | View on chart |
| TYRA | ▲ Buy | Open Market | 625,000 | $10.0M | 9/17/2021 | View on chart |
| TYRA | ▼ Sell | Other | 288,095 | — | 9/17/2021 | View on chart |
| TYRA | ▼ Sell | Other | 5,698,359 | — | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop
Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.